Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol.

Jeroen H A CreemersInka PawlitzkyKonstantina GrosiosUzi GileadiMark R MiddletonWinald R GerritsenNiven MehraLicia RivoltiniIan WaltersCarl G FigdorPetronella B OttevangerI Jolanda M de Vries

Published in: BMJ open (2021)

NCT04751786.

Keyphrases

open label
study protocol
phase ii
clinical trial
phase iii
phase ii study
endothelial cells
randomized controlled trial
drug delivery
induced pluripotent stem cells
pluripotent stem cells
double blind
young adults
walled carbon nanotubes
locally advanced